Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 731 clinical trials
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

type 1 diabetes mellitus
hair thinning
carcinoma
liver transplant
renal function test
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

chronic myelomonocytic leukemia
high risk myelodysplastic syndrome
cell transplantation
cmml-2
myelomonocytic leukemia
  • 0 views
  • 16 Feb, 2024
  • 23 locations
NA-831 Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

combination therapy
complete blood count
critical illness
electrocardiogram (ecg)
intrauterine device (iud)
  • 0 views
  • 16 Feb, 2024
  • 30 locations
Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in …

thrombocytopenia
pivka-ii
carcinoma
liver transplant
ascites
  • 0 views
  • 05 Aug, 2020
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

chemoradiotherapy
mitomycin
metastatic bladder carcinoma
pembrolizumab
invasive bladder cancer
  • 0 views
  • 16 Feb, 2024
  • 33 locations
  • 0 views
  • 24 May, 2024
  • 2 locations
Study title (acronymtest)  

study overview

Accepts healthy volunteers
  • 0 views
  • 02 Mar, 2026
V6.3 Additional &QA123  

Test Comment here

  • 0 views
  • 24 Aug, 2023
  • 4 locations
Stress Management and Biological Age in Breast Cancer Patients.RCT  

Intense stress has harmful effects on the body, contributing to various disorders. Breast cancer patients experience a build-up of stress due to their diagnosis and treatments. Stress can cause epigenetic changes in a cellular level (such as accelerated increase in biological age) that may negatively affect oncological treatments. This study …

  • 0 views
  • 03 Oct, 2023
  • 13 locations
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib or Binimetinib as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. This research study involves three study drugs. Lorlatinib Binimetinib Crizotinib

prophylaxis
levetiracetam
non-small cell lung cancer
ascites
lorlatinib
  • 0 views
  • 16 Feb, 2024
  • 2 locations